We are live on ! Find out more
KZIA icon

Kazia Therapeutics

9 hedge funds and large institutions have $236K invested in Kazia Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more funds holding

Funds holding: 8 → 9 (+1)

0.39% less ownership

Funds ownership: 1.39% → 1% (-0.39%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

74% less capital inflows, than outflows

Capital inflows: $16.5K | Capital outflows: $62.6K

Holders
9
Holders Change
+1
Holders Change %
+12.5%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
+$11.4K
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$5.08K

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$48.3K
2
Morgan Stanley
Morgan Stanley
New York
-$14.3K

KZIA Hedge Fund Activity: Q3 2023 in Review

9 of the 6,317 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q3 2023, worth a combined $236K — down 28% from $328K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new KZIA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $11.4K. The largest seller was Acadian Asset Management, cutting an estimated $48.3K.

  • 9 institutional investors held Kazia Therapeutics (KZIA) as of Q3 2023, up from 8 in Q2 2023.
  • Funds reported $236K of Kazia Therapeutics stock for Q3 2023, down 28% quarter-over-quarter.
  • 1 fund opened new Kazia Therapeutics positions in Q3 2023 and 0 closed out, a net change of +1 holder.
  • The largest Kazia Therapeutics buyer in Q3 2023 was Virtu Financial, an estimated $11.4K added.
  • The largest Kazia Therapeutics seller in Q3 2023 was Acadian Asset Management, an estimated $48.3K sold.

Based on aggregated 13F filings for Q3 2023.